从降糖减重到心血管保护! Mounjaro完成“心代谢跃迁”,礼来(LLY.US)打开GLP-1第二增长曲线

智通财经
Aug 28
【从降糖减重到心血管保护! Mounjaro完成“心代谢跃迁”,礼来(LLY.US)打开GLP-1第二增长曲线】智通财经APP获悉,美国医疗保健行业领军者礼来公司(LLY.US)正在将重磅减肥药——即有着“减肥神药”称号且具有降糖疗效的Mounjaro从降糖与减重产品定位全方位升级为覆盖心血管与代谢并发症的综合治疗平台。美国食品药品监督管理局此次批准Mounjaro用于降低伴有心脏病的2型糖尿病成人发生心血管死亡、非致死性心肌梗死或非致死性卒中的风险,进一步增强其相对于最大规模竞争对手诺和诺德旗下减肥与降糖药Ozempic的竞争优势。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10